EyeCool Therapeutics Announces Publication of Positive Clinical Study Results for Its COSP Device

CAMBRIDGE, Mass. - Rezul -- EyeCool Therapeutics today announced the publication of a prospective study evaluating its investigational ophthalmic cooling device, ETX-4143, for the treatment of chronic ocular surface pain (COSP). The positive findings further support the development of precision ocular cooling as a potential new therapeutic category for chronic ocular surface pain, demonstrating that a single in-office treatment was associated with significant reductions in ocular pain for up to 12 weeks while preserving corneal nerve morphology and ocular surface health.

The study, "Impact of an Ophthalmic Cooling Device on Corneal Immune and Sensory Nerve Features in Chronic Ocular Surface Pain: A Prospective, Feasibility Study," evaluated the safety and biological effects of ETX-4143 in adults with chronic ocular surface pain. In this prospective paired-eye feasibility study, five participants received a single 4-minute treatment in their more symptomatic eye using the investigational cooling device, while the fellow eye served as an untreated control. Participants were followed for 12 weeks with comprehensive clinical assessments and advanced corneal in vivo confocal microscopy. See full research paper (https://link.springer.com/article/10.1007/s40123-026-01454-6).

More on Rezul News

• AI Visibility Labs LLC - Dallas Texas - July 16 2026
• NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)
• Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers
• Where Is Your Faith The Movie and Sountrack
• Bynn Intelligence Ranks #1 in NIST Child Online Safety Evaluation for Ages 13–16

Relative to baseline, ocular pain severity was significantly reduced at 2, 6, and 12 weeks following treatment, with maintained effect over time. Clinical assessments demonstrated that visual acuity, tear osmolarity, corneal sensitivity, ocular surface integrity, and corneal nerve morphology remained stable throughout the study, supporting the favorable safety profile of ETX-4143.

Notably, use of the advanced functional in vivo confocal microscopy (Fun-IVCM) technique for exploratory endpoints revealed changes in corneal immune cell behavior following treatment. Investigators observed increased motility of putative intraepithelial T cells during the early post-treatment period, followed by reductions in both T-cell motility and dendritic cell probing behavior at 12 weeks. These findings suggest that localized cooling adjacent to the cornea may influence corneal immune dynamics, although the authors note that these observations are only exploratory and hypothesis-generating at this point.

The study concluded that, within this participant cohort, ETX-4143 had indicators of a favorable safety profile while improving pain outcomes and modulating corneal immune dynamics through 12 weeks after treatment. The authors noted that larger, randomized controlled trials are warranted to further evaluate the clinical efficacy, durability, and mechanisms of treatment.

More on Rezul News

• Rev-O-Box™ Launches Reversible Shipping Box That Instantly Becomes a Premium Gift Box
• Las Vegas Estate Firm Ghandi Deeter Blackham Offers Insight on Tony Hsieh's Contested $500 Million Will
• Trang Hooser Launches Elite Relocation Division as Athletes and Entertainers Reshape Las Vegas
• CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
• Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe

Together, these findings strengthen the scientific rationale for precision ocular cooling as a distinct therapeutic approach for chronic ocular surface pain, a condition for which there are currently no FDA-approved treatments.

About EyeCool Therapeutics Inc.

EyeCool Therapeutics is a clinical-stage medical device company pioneering precision ocular cooling as a potential new therapeutic category for chronic ocular surface pain.

Important Safety Information

Warning: This product has not been approved or cleared for marketing by the U.S. Food and Drug Administration and is considered an investigational device. For more info, please visit www.eyecooltx.com.